Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in…
Month: November 2020
Agile Therapeutics Reports Third Quarter 2020 Financial Results
Commercial Launch of Twirla® Expected by Year-End 2020 $71.9 Million in Cash, Cash Equivalents, and…
Relay Therapeutics Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
Motus GI Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the…
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
NGM continues to demonstrate the productivity of its research discovery engine and progress against its…
Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, Mass., Nov. 12,…
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022,…
Applied Molecular Transport Reports Third Quarter 2020 Financial Results and Provides Corporate Update
– Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including…
LogicBio Therapeutics to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated…
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020
PORTLAND, Maine, Nov. 12, 2020 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”),…
Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH…
Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical…
Retrophin Completes Acquisition of Orphan Technologies
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases SAN DIEGO, Nov….
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
– LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate…
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA),…
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data…
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results
DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a…
Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a…